Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1012D vs Gonal-F PK and Safety in Healthy Females
NCT06864793Phase 1Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL1012 in female infertility (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum plasma concentration at 216 hours and Area under the curve at 216 hours. Started Apr 2025; status: active, not recruiting.
02
Drugs
QL1012
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT06864793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864793.